# FDA recall D-1309-2014

> **Merck & Co Inc** · Class III · drug recall initiated 2014-01-13.

## Product

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/10 mg, a) 30 count blister    (NDC 66582-320-30), b) 90 count blister  (NDC 66582-320-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

## Reason for recall

This recall of LIPTRUZET is being initiated due to  packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

## Distribution

Nationwide and Puerto Rico

## Key facts

- **Recall number:** D-1309-2014
- **Recalling firm:** Merck & Co Inc
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2014-01-13
- **Report date:** 2014-05-14
- **Termination date:** 2015-09-02

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Whitehouse Station, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1309-2014

## Citation

> AI Analytics. FDA recall D-1309-2014. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-1309-2014. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*